CAM2029 octreotide subcutaneous depot provides stable control of IGF-I and improves key symptoms throughout a 4-week post-dose interval: analysis from the ACROINNOVA 1 trial

Oclaiz (octreotide subcutaneous depot) - Camurus

https://ese-hormonesdistribute.m-anage.com/from.storage?image=q5B08HqJEWT974SjeAc7JlgwWvT_CUsnz4Fp6Rqmbwt9tm5Adw4XTyHqGcGDDfvl0

Monica R. Gadelha * 1; Beverly M.K. Biller 2; Maria Fleseriu 3; Joanna L. Spencer-Segal 4; Julie M. Silverstein 5; Irina Bancos 6; Jacob Råstam 7; Alberto M. Pedroncelli 7; Fredrik Tiberg 7; Diego Ferone 8

Apr 10, 2025